Advances in bioinformatics and genomic data
analysis have enabled the identification of cancer antigens that are generally
overlooked during immune surveillance; these neoantigens have been shown to
possess substantial therapeutic potential
London
Roots Analysis has announced the addition of “Neoantigen Targeted Therapies, 2019-2030” report to its list of offerings.
The
use of neoantigens in therapy has demonstrated the ability to elicit a strong T
cell mediated immune response. Several therapy candidates are being
investigated both as monotherapies and in combination with various immune
checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and
nivolumab. Of these, certain pipeline candidates have already entered mid to
late-stage (phase II and above) trials and are anticipated to enter the market over
the next 5-10 years.
To order this 320+ page report,
which features 110+ figures and 140+ tables, please visit this link
Key Market Insights
Over 150+ candidate therapies in the development pipeline
Nearly
13% of the pipeline therapies are being developed for the treatment of GI
cancers, followed by lung cancer (11%). Examples of molecules being developed
for the aforementioned indications include (in alphabetical order, no
specific selection criteria) MicOryx, NCI-4650, and Tedopi®.
1,100+ patents filed / granted in 2018
In fact, more than 6,000 patents were filed / granted related
to neoantigen targeted therapies, since 1978. Based on existing intellectual
property, the R&D activity was observed to be concentrated in the US. Other
key regions with significant intellectual capital include (in decreasing
order of number of patents filed / granted) Australia, Europe, China, and
Canada.
Close to USD 7.5 billion invested by both private and public
investors, since 2014
Around USD 3,200 million was raised through venture capital
financing, representing around 43% of the total capital raised by industry
players in the given time period (till April 2019). Further, in the last five
years, there have been 10 IPOs accounting for more than 800 million in
financing of neoantigen related initiatives.
Companies are collaborating actively for the advancement of
clinical trials
Majority of the abovementioned agreements were observed to
be focused on conducting Phase I / Phase II clinical studies of neoantigen
targeted therapies for the treatment of different cancer indications. Agreements
signed for research purposes (19%) were also observed to be popular among
industry stakeholders, during 2014-2019 (till April).
More than 350 publications have
been published since 2014
It is worth noting that between the period 2014-2019, over
150 research articles were published related to neoantigen targeted therapies.
Further, more than 190 review articles have been published related to this
upcoming field.
Therapies using personalized neoantigens are anticipated to
increase at a CAGR of over 60% between 2024 and 2030
This growth is anticipated to be primarily driven by the reduced
risk of adverse effects and improved efficacy of personalized therapies.
North America (primarily the US) and Europe are expected to capture the
majority share by 2030, in terms of the sales-based revenues.
Press
Release: Current Format
To
request a sample copy / brochure of this report, please visit this link
Key Questions Answered
§ What are the prevalent trends related to R&D activity
focused on neoantigen based therapies?
§ What are the clinical conditions for which neoantigen
targeted therapies are being developed?
§ What are the key challenges faced by neoantigen-based
therapy developed?
§
§
§
§
§
§ How is the current and future market opportunity likely to
be distributed across key market segments and geographies?
The USD 3 billion (by 2030)
financial opportunity within the neoantigens market has been analyzed across
the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The
report features inputs from eminent industry stakeholders, according to whom neoantigen
targeted therapies are expected to be the next big step in cancer
immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated
significant therapeutic potential and promising clinical outcomes. The
report includes detailed transcripts of discussions held with the following
experts:
§ Gabriel
Nistor (Chief Science Officer, AIVITA Biomedical)
§ Ella
Sorani (Vice President Research and Development, BioLineRx)
§ Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)
Press
Release: Current Format
The
research covers detailed profiles, featuring an overview of the company, its
financial information (if available),
and a description of its product(s), highlighting type of therapy, current
development status, and key preclinical / clinical trial results. Each profile
also includes a list of recent developments, and an informed opinion on the
likely strategies that may be adopted by these players to fuel growth in the
foreseen future.
§
§
§
§
§
§
§
§
§
§
For
additional details, please visit
https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
or email sales@rootsanalysis.com
You
may also be interested in the following titles:
1. T-Cell Immunotherapies Market (4th
Edition), 2019-2030
2. Novel Immuno-Oncology Biomarker
Testing Market, 2019-2030
3. Companion Diagnostics Market (2nd
Edition), 2019-2030
Contact:
Gaurav
Chaudhary
+1 (415) 800 3415